The subcutaneous defibrillator.

Area of Science:

• Cardiology
• Medical Devices
• Electrophysiology

Background:

• Sudden cardiac death (SCD) remains a significant clinical challenge.
• Current strategies involve risk stratification and comorbidity management.
• Some patients remain at high risk despite optimal medical therapy or have nonmodifiable risks.

Purpose of the Study:

• To discuss the role of device therapy in SCD prevention.
• To highlight the risks associated with traditional implantable cardioverter-defibrillators (ICDs) and their endovascular leads.
• To introduce the subcutaneous ICD (S-ICD) as a potentially safer alternative.

Main Methods:

• Review of current literature and clinical practice regarding SCD prevention.
• Discussion of the technological advancements and implantation procedure of the S-ICD.
• Analysis of patient populations that may benefit from S-ICD therapy.

Main Results:

• Traditional ICDs, while effective, carry risks related to lead placement and chronic lead presence.
• Lead complications, including malfunction and extraction, contribute to significant morbidity and mortality.
• The S-ICD system avoids transvenous leads, mitigating risks associated with endovascular components.

Conclusions:

• The S-ICD may be a preferred option for specific patient groups, including young individuals, those with inherited channelopathies, immunocompromised patients, or those with challenging venous access.
• While long-term data are pending, the S-ICD shows promise as an effective therapeutic option for SCD prevention.
• The S-ICD offers a potentially reduced-risk profile compared to transvenous ICDs.